The invention is directed to substituted benzimidazol-2-ones of Formula I, ##STR1## wherein A, X, Y, m, n, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are as described in the specification, which are useful as vasopressin receptor antagonists or Neuropeptide Y Modulators for treating conditions such as aggression, obsessive-compulsive disorders, hypertension, dysmenorrhea, congestive heart failure/cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, edema, ischemia, stroke, thrombosis, water retention, nephrotic syndrome, central nervous injuries, obesity, anorexia, hyperglycemia, diabetes, anxiety, depression, asthma, memory loss, sexual dysfunction, disorders of sleep and other circadian rhythms, and Cushing's disease.

A invenção é dirigida a benzimidazol-2-ones substituído da fórmula I, ## wherein A, X, Y, m, n, R.sub.1, R.sub.2, R.sub.3, R.sub.4, e R.sub.5 são como descritos na especificação, que são úteis como antagonistas do receptor do vasopressin ou moduladores de Neuropeptide Y para condições de tratamento tais como o aggression, disorders obsessive-obsessive-compulsive do ## STR1, hypertension, dysmenorrhea, insufficiency congestive do coração failure/cardiac, vasospasm coronary, ischemia cardiac, cirrhosis de fígado, vasospasm renal, falha renal, edema, ischemia, curso, thrombosis, retenção da água, syndrome nephrotic, os ferimentos nervosos centrais, obesity, anorexia, hyperglycemia, diabetes, ansiedade, depression, asthma, memória perda, dysfunction sexual, disorders do sono e outros ritmos circadian, e doença de Cushing.